Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction
Authors:
Open Access
- 21 September 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 33953
Abstract
Fibroblast growth factor 21 (FGF21), a polypeptide ligand promoted glucose homeostasis and lipids metabolism, was recently reported to attenuate cardiac hypertrophy. The aim of this study was to investigate the impact of FGF21 in diastolic heart failure. Subjects admitted for coronary angiogram were screened for heart failure and those with left ventricular (LV) ejection fraction < 45% were excluded. Diastolic dysfunction was defined as functional abnormalities that exist during LV relaxation and filling by echocardiographic criteria. Plasma levels of FGF21 and N-terminal Pro-Brain Natriuretic Peptide (NT-pro-BNP) were determined. All patients were followed up for 1 year, or till the occurrence of heart failure readmission or death. Totally 95 patients with diastolic dysfunction and 143 controls were enrolled. Circulating FGF21 level was correlated with echocardiographic parameters of diastolic function and LV end-diastolic pressure (LVEDP). In multivariate logistic analysis, FGF21 was significantly associated with diastolic dysfunction, either identified by echocardiographic criteria (odds ratio: 2.97, p = 0.012) or confirmed with LVEDP level (odds ratio: 3.73, p = 0.030). Both plasma FGF21 (log rank p < 0.0001) and NT-pro-BNP levels (log rank p = 0.0057) showed good predictive power to the 1-year adverse cardiac events. This finding suggested FGF21 could be involved in the pathophysiology of diastolic heart failure.Keywords
This publication has 38 references indexed in Scilit:
- Additive relationship between serum fibroblast growth factor 21 level and coronary artery diseaseCardiovascular Diabetology, 2013
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult MouseMolecular Endocrinology, 2010
- Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese RatsDiabetes, 2010
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlothoJournal of Cellular Physiology, 2007
- The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic CardiomyopathyJACC, 2006
- FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation, 2005
- Impact of Different Partition Values on Prevalences of Left Ventricular Hypertrophy and Concentric Geometry in a Large Hypertensive PopulationHypertension, 2000
- Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.Circulation, 1977